Liu DKY, Senn S, Howard R. Avoiding causal fraud in the evaluation of clinical benefits of treatments for Alzheimer's disease. Alzheimers Dement. 2025;21:e14457. doi:10.1002/alz.14457
Hazan J, Liu KY, Isaacs JD, Howard R. Cut‐points and gray zones: the challenges of integrating Alzheimer's disease plasma biomarkers into clinical practice. Alzheimers Dement. 2025;21:e70113. doi:10.1002/alz.70113
Liu KY, Senn, S. and Howard R. Response to letter to the editor. Alzheimers Dement. 2025;21: e70251. doi:10.1002/alz.70251
Following publication of the articles listed above, it was identified that a conflict of interest disclosure for author Robert Howard was inadvertently omitted from the published versions.
The following conflict of interest disclosure should have appeared in each article:
Robert Howard was a member of a Scientific Advisory Board for Synaptogenix from 2022 to 2023.
The conflict of interest disclosure has been added to the online version of each article. This correction notice has been published to document the addition of the disclosure.
We apologize for this error.